Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.31
OPK's Cash-to-Debt is ranked lower than
55% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. OPK: 1.31 )
Ranked among companies with meaningful Cash-to-Debt only.
OPK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 18 Max: No Debt
Current: 1.31
Equity-to-Asset 0.76
OPK's Equity-to-Asset is ranked higher than
70% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OPK: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
OPK' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.69 Max: 0.96
Current: 0.76
-0.41
0.96
Piotroski F-Score: 3
Altman Z-Score: 3.67
Beneish M-Score: -2.36
WACC vs ROIC
14.62%
-2.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -7.13
OPK's Operating Margin % is ranked lower than
77% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. OPK: -7.13 )
Ranked among companies with meaningful Operating Margin % only.
OPK' s Operating Margin % Range Over the Past 10 Years
Min: -31624.44  Med: -82.69 Max: -6
Current: -7.13
-31624.44
-6
Net Margin % -3.59
OPK's Net Margin % is ranked lower than
75% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. OPK: -3.59 )
Ranked among companies with meaningful Net Margin % only.
OPK' s Net Margin % Range Over the Past 10 Years
Min: -31688.9  Med: -92.47 Max: -2.05
Current: -3.59
-31688.9
-2.05
ROE % -2.14
OPK's ROE % is ranked lower than
71% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. OPK: -2.14 )
Ranked among companies with meaningful ROE % only.
OPK' s ROE % Range Over the Past 10 Years
Min: -3196.93  Med: -20.87 Max: -1.23
Current: -2.14
-3196.93
-1.23
ROA % -1.59
OPK's ROA % is ranked lower than
71% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. OPK: -1.59 )
Ranked among companies with meaningful ROA % only.
OPK' s ROA % Range Over the Past 10 Years
Min: -1352.71  Med: -13.26 Max: -0.83
Current: -1.59
-1352.71
-0.83
ROC (Joel Greenblatt) % -36.79
OPK's ROC (Joel Greenblatt) % is ranked lower than
79% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. OPK: -36.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -130662.93  Med: -258.52 Max: -36.79
Current: -36.79
-130662.93
-36.79
3-Year Revenue Growth Rate 101.30
OPK's 3-Year Revenue Growth Rate is ranked higher than
98% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. OPK: 101.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OPK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26 Max: 152
Current: 101.3
0
152
3-Year EPS without NRI Growth Rate -46.30
OPK's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. OPK: -46.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.4  Med: -9.3 Max: 152.4
Current: -46.3
-69.4
152.4
GuruFocus has detected 2 Warning Signs with OPKO Health Inc $OPK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPK's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:AKRX, OTCPK:STDAF, NYSE:MNK, NYSE:CTLT, NYSE:TARO, OTCPK:HKMPY, NAS:IRWD, NAS:MDCO, NYSE:PTHN, NAS:ENDP, OTCPK:HYPMY, NYSE:VRX, NAS:SUPN, OTCPK:EVTCY, NAS:RDUS, NAS:HZNP, NAS:PCRX, NAS:PAHC, NAS:MNTA, NAS:EGRX » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Headquarter Location:USA
OPKO Health Inc is a diversified healthcare company. Its business includes diagnostics and provision of pharmaceutical products.

Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

Ratios

vs
industry
vs
history
PB Ratio 1.79
OPK's PB Ratio is ranked higher than
69% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. OPK: 1.79 )
Ranked among companies with meaningful PB Ratio only.
OPK' s PB Ratio Range Over the Past 10 Years
Min: 1.68  Med: 8.44 Max: 800
Current: 1.79
1.68
800
PS Ratio 3.08
OPK's PS Ratio is ranked lower than
52% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. OPK: 3.08 )
Ranked among companies with meaningful PS Ratio only.
OPK' s PS Ratio Range Over the Past 10 Years
Min: 2.87  Med: 31.62 Max: 158.13
Current: 3.08
2.87
158.13
Price-to-Operating-Cash-Flow 571.66
OPK's Price-to-Operating-Cash-Flow is ranked lower than
98% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.13 vs. OPK: 571.66 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OPK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 20.6  Med: 43.78 Max: 676.67
Current: 571.66
20.6
676.67
EV-to-EBITDA 136.11
OPK's EV-to-EBITDA is ranked lower than
96% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.55 vs. OPK: 136.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6  Med: -34 Max: 539.9
Current: 136.11
-146.6
539.9
Current Ratio 1.74
OPK's Current Ratio is ranked lower than
65% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. OPK: 1.74 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 5.3 Max: 415
Current: 1.74
0.88
415
Quick Ratio 1.56
OPK's Quick Ratio is ranked lower than
57% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. OPK: 1.56 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.75 Max: 415
Current: 1.56
0.48
415
Days Inventory 26.02
OPK's Days Inventory is ranked higher than
93% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. OPK: 26.02 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 25.94  Med: 191.87 Max: 500.07
Current: 26.02
25.94
500.07
Days Sales Outstanding 71.08
OPK's Days Sales Outstanding is ranked higher than
54% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. OPK: 71.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 153.78 Max: 727.85
Current: 71.08
38.86
727.85
Days Payable 43.98
OPK's Days Payable is ranked lower than
73% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.86 vs. OPK: 43.98 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 31.85  Med: 108.04 Max: 1499.3
Current: 43.98
31.85
1499.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.60
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. OPK: -10.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3  Med: -14.4 Max: 0.4
Current: -10.6
-146.3
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 343.00
OPK's Price-to-Tangible-Book is ranked lower than
100% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. OPK: 343.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OPK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.35  Med: 10.28 Max: 850
Current: 343
0.35
850
Price-to-Intrinsic-Value-Projected-FCF 2.59
OPK's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
56% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. OPK: 2.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OPK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.53  Med: 10.97 Max: 177.5
Current: 2.59
2.53
177.5
Price-to-Median-PS-Value 0.10
OPK's Price-to-Median-PS-Value is ranked higher than
99% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. OPK: 0.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 1.29 Max: 30
Current: 0.1
0.1
30
Earnings Yield (Greenblatt) % -1.92
OPK's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. OPK: -1.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.7  Med: -2.7 Max: 0.5
Current: -1.92
-26.7
0.5

More Statistics

Revenue (TTM) (Mil) $1,226.72
EPS (TTM) $ -0.10
Beta2.15
Short Percentage of Float22.01%
52-Week Range $5.99 - 12.15
Shares Outstanding (Mil)559.39

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,244 1,389 1,550
EPS ($) -0.28 -0.17 0.03
EPS without NRI ($) -0.28 -0.17 0.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)
» More Articles for OPK

Headlines

Articles On GuruFocus.com
OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD Jun 22 2017 
OPKO’S GeneDx Extends Relationship with University of California Health for Genetic and Molecul Jun 07 2017 
OPKO Health Provides Commercial Update for RAYALDEE Jun 05 2017 
Weekly CEO Buys Highlight May 29 2017 
MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering May 22 2017 
OPKO Announces Multiple Presentations at the 112th American Urological Association Annual Meeting May 15 2017 
Weekly CEO Buys Highlights May 15 2017 
CORRECTION -- OPKO Health Inc. May 09 2017 
OPKO Health Reports 2016 Financial and Operating Results May 09 2017 
OPKO Health to Announce 2017 First Quarter Financial Results on May 9, 2017 May 08 2017 

More From Other Websites
ETFs with exposure to OPKO Health, Inc. : June 26, 2017 Jun 26 2017
How Things Look for Opko Health, Inc. in 3 Charts Jun 26 2017
Xenetic Biosciences Commences Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction... Jun 26 2017
OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD Jun 22 2017
OPKO Health, Inc. breached its 50 day moving average in a Bullish Manner : OPK-US : June 22, 2017 Jun 22 2017
OPKO Provides Update to Topline Data of Phase 3 Clinical Study of hGH-CTP in Growth Hormone... Jun 15 2017
OPKO Health, Inc. :OPK-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Jun 14 2017
Today's Research Reports on Stocks to Watch: Exelixis and Opko Health Jun 13 2017
OPKO’S GeneDx Extends Relationship with University of California Health for Genetic and Molecular... Jun 07 2017
OPKO Health Provides Commercial Update for RAYALDEE Jun 05 2017
Here's Why Opko Health Inc. Slipped 18.8% in May Jun 05 2017
James J. Martin Appointed as Chief Financial Officer of Cocrystal Pharma, Inc. Jun 01 2017
Is the Options Market Predicting a Spike in Opko Health (OPK) Stock? May 25 2017
3 Value Stocks You Might Not Have Thought Of May 25 2017
Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656... May 22 2017
MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering May 22 2017
OPKO Health’s 4Kscore® Test Highlighted in Podium Presentation at 112th American Urological... May 18 2017
Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update May 16 2017
Edited Transcript of OPK earnings conference call or presentation 9-May-17 8:30pm GMT May 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}